Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Prosperini

Showing results (151-160 of 182) with videos related to

Pageof 19
Sort By:
Journal of Neurology|November 24, 2016
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosisLuca Prosperini, Francesco Saccà, Cinzia Cordioli, et al.
Journal of Neurology|October 1, 2021
Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patientsJordi Río, Àlex Rovira, Claudio Gasperini, et al.
Journal of Neurology|November 20, 2021
Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patientsJordi Río, Àlex Rovira, Claudio Gasperini, et al.
Annals of Neurology|June 18, 2026
From Marginal to Central: Marginal Zone-like B Cells as Critical Targets in Cladribine-Treated Multiple SclerosisMarta Pirronello, Mario Picozza, Gisella Guerrera, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 4, 2025
Epilepsy in MS and its association with cognitive and psychological burdenValeria Pozzilli, Carla Tortorella, Luca Prosperini, et al.
Neurology|December 28, 2018
Unraveling treatment response in multiple sclerosis: A clinical and MRI challengeClaudio Gasperini, Luca Prosperini, Mar Tintoré, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 5, 2018
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosisDoriana Landi, Paolo Ragonese, Luca Prosperini, et al.
Journal of Neurology|September 28, 2018
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Pietro Annovazzi, Laura Boffa, et al.
Frontiers in Immunology|November 17, 2025
Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapiesAlessandra Aiello, Assunta Navarra, Shalom Haggiag, et al.
International Journal of Molecular Sciences|May 27, 2023
Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster DoseSerena Ruggieri, Alessandra Aiello, Carla Tortorella, et al.
Pageof 19

Showing results (151-160 of 182) with videos related to

Sort By:
Pageof 19
Journal of Neurology|November 24, 2016
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosisLuca Prosperini, Francesco Saccà, Cinzia Cordioli, et al.
Journal of Neurology|October 1, 2021
Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patientsJordi Río, Àlex Rovira, Claudio Gasperini, et al.
Journal of Neurology|November 20, 2021
Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patientsJordi Río, Àlex Rovira, Claudio Gasperini, et al.
Annals of Neurology|June 18, 2026
From Marginal to Central: Marginal Zone-like B Cells as Critical Targets in Cladribine-Treated Multiple SclerosisMarta Pirronello, Mario Picozza, Gisella Guerrera, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 4, 2025
Epilepsy in MS and its association with cognitive and psychological burdenValeria Pozzilli, Carla Tortorella, Luca Prosperini, et al.
Neurology|December 28, 2018
Unraveling treatment response in multiple sclerosis: A clinical and MRI challengeClaudio Gasperini, Luca Prosperini, Mar Tintoré, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 5, 2018
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosisDoriana Landi, Paolo Ragonese, Luca Prosperini, et al.
Journal of Neurology|September 28, 2018
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Pietro Annovazzi, Laura Boffa, et al.
Frontiers in Immunology|November 17, 2025
Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapiesAlessandra Aiello, Assunta Navarra, Shalom Haggiag, et al.
International Journal of Molecular Sciences|May 27, 2023
Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster DoseSerena Ruggieri, Alessandra Aiello, Carla Tortorella, et al.
Pageof 19